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Abstract
Background: Two randomised, double-blind, placebo-controlled trials have investigated the efficacy of IV alpha-1
antitrypsin (AAT) augmentation therapy on emphysema progression using CT densitometry.
Methods: Data from these similar trials, a 2-center Danish-Dutch study (n = 54) and the 3-center EXAcerbations
and CT scan as Lung Endpoints (EXACTLE) study (n = 65), were pooled to increase the statistical power. The
change in 15
th percentile of lung density (PD15) measured by CT scan was obtained from both trials. All subjects
had 1 CT scan at baseline and at least 1 CT scan after treatment. Densitometric data from 119 patients (AAT
[Alfalastin® or Prolastin®], n = 60; placebo, n = 59) were analysed by a statistical/endpoint analysis method. To
adjust for lung volume, volume correction was made by including the change in log-transformed total lung
volume as a covariate in the statistical model.
Results: Mean follow-up was approximately 2.5 years. The mean change in lung density from baseline to last CT
scan was -4.082 g/L for AAT and -6.379 g/L for placebo with a treatment difference of 2.297 (95% CI, 0.669 to
3.926; p = 0.006). The corresponding annual declines were -1.73 and -2.74 g/L/yr, respectively.
Conclusions: The overall results of the combined analysis of 2 separate trials of comparable design, and the only 2
controlled clinical trials completed to date, has confirmed that IV AAT augmentation therapy significantly reduces
the decline in lung density and may therefore reduce the future risk of mortality in patients with AAT deficiency-
related emphysema.
Trial registration: The EXACTLE study was registered in ClinicalTrials.gov as ‘Antitrypsin (AAT) to Treat Emphysema
in AAT-Deficient Patients’; ClinicalTrials.gov Identifier: NCT00263887.
Introduction
In subjects with a hereditary deficiency of alpha-1 anti-
trypsin (AAT), the pathophysiology of emphysema is
believed to be a direct consequence of tissue damage
caused by a reduced ability of AAT to inactivate neutro-
phil elastase, which is released by migrating neutrophils
in response to inflammatory stimuli [1]. It is logical that
augmentation of the circulating levels (and hence lung
levels) of AAT would confer normal protection by
restoring the inhibitory capacity of AAT in the lungs.
The net result is argued to be retardation of the
destructive process and, therefore, the progressive
decline in lung physiology [2]. A strategy of weekly aug-
mentation with AAT was thus introduced in the 1980s,
confirming that the attainment of a putative protective
level was possible with weekly infusions of AAT at a
dose of 60 mg￿kg
-1 body weight [3].
Because the numbers required to perform a controlled
clinical trial using forced expiratory volume in 1 second
(FEV1) are thought to be prohibitive (requiring inclusion
of a large number of individuals with a rare disease over
many years [4,5]), no such study has been undertaken.
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using varying treatment intervals and doses of plasma-
derived AAT [6].
In the past, the mainstay of clinical assessment of
emphysema was lung function and especially gas transfer
measurements, although recent data have indicated that
there is differential progression depending on disease
severity [7]. Computed tomography (CT) densitometry is a
validated and more direct measure of pathological emphy-
sema [8-10] that relates well to physiological and clinical
features of disease [11,12], progresses uniformly across dis-
ease severity [10] and has specifically been shown to be the
best independent predictor of mortality [13].
In 1999, Dirksen, et al reported a 3-year Danish-
Dutch controlled study of intravenous (IV) AAT aug-
mentation therapy, with loss of lung tissue measured by
CT densitometry as a secondary outcome parameter in
56 patients [14]. The study suggested a reduction in
emphysema progression with AAT augmentation ther-
apy measured by CT, although the p value for the treat-
ment difference obtained (p = 0.07) failed to achieve the
conventional level of significance, which may reflect the
number of subjects in the trial.
More recently, the EXAcerbations and CT scan as
Lung Endpoints (EXACTLE) study (77 patients studied
over 24-30 months), using a similar placebo-controlled
trial design of IV AAT, explored CT densitometry as the
primary outcome [15]. Lung density was analysed using 4
different methods of adjustment that corrected for varia-
tion in inspiratory levels between scans, and all showed a
trend towards efficacy. However, endpoint analysis using
a statistical correction for lung volume not only proved
to be the most sensitive method of analysis (based on
monitoring progression in the placebo group), but also
achieved a conventional level of statistical significance
with regard to lung tissue loss between both treatment
groups. Interestingly, in both the Danish-Dutch and
EXACTLE studies, there was little difference in density
loss between the AAT and placebo groups within the
first year while, subsequently, the difference between the
groups increased with time. Furthermore, the effect of
therapy in clinical trials is usually determined by end-
point analysis. For these reasons, we chose to re-analyse
the Danish-Dutch study using an endpoint analysis,
utilising only the first and last available measurement.
In addition, because of the similar study design and
method of CT densitometry, we combined the raw data
from both studies to increase the statistical power as
suggested in the previous Danish-Dutch study [14].
Materials and methods
C h a r a c t e r i s t i c so ft h es t u d ys u b j e c t sa n dd e s i g n so ft h e
Danish-Dutch and EXACTLE studies are presented in
Table 1. Full methodological details, together with
further details of the patient inclusion and exclusion cri-
teria for the 2 studies, can be found in the original pub-
lications [14,15].
Patients
Pooled patient data from the 2 previously described
trials, the 2-centre Danish-Dutch study (Copenhagen,
Denmark; Leiden, The Netherlands) [14] and the
3-centre EXACTLE study (Copenhagen, Denmark;
Birmingham, United Kingdo m ;M a l m ö ,S w e d e n )[ 1 5 ] ,
are summarised in Table 2. All patients had been
recruited from AAT deficiency registries. The Danish-
Dutch study randomised 56 patients and there were 77
from EXACTLE; in total, 125 patients were valid for CT
data analysis (Figure 1). However, 6 patients originally
enrolled in the Danish-Dutch trial also participated in
the EXACTLE study. The data for these 6 subjects from
EXACTLE were therefore excluded from the integrated
analysis. The original studies had been approved by
local ethics committees and were conducted in accor-
dance with the Declaration of Helsinki and Good Clini-
cal Practice Guidelines.
Study designs
Both studies were randomised, placebo-controlled, double-
blind, parallel-group trials [14,15]. Patients in the Danish-
Dutch study were randomised to receive infusions of
either AAT (Alfalastin®; Laboratoire Français du Fraction-
nement et des Biotechnologies, 3 avenue des Tropiques,
BP 305, Les Ulis, 91958 Courtaboeuf Cedex, France;
250 mg￿kg
-1 body weight) or placebo (human albumin
solution; 625 mg￿kg
-1 body weight) every 4 weeks for
≥3 years [14]. Patients in the EXACTLE study were rando-
mised to weekly infusions of AAT (Prolastin®; Talecris
Biotherapeutics, Inc., Research Triangle Park, NC, USA;
60 mg￿kg
-1 body weight) or placebo (2% albumin) for
24 months, with an optional extension to 30 months in
subjects who agreed to continue in the study [15].
Data analysis and CT densitometry
The rate of emphysema progression was determined by
change in lung density measured by whole lung CT
scan, and reported as the annual change in the 15
th per-
centile lung density (PD15) (determined from the end-
point in the original trials). The PD15 value is extracted
from the frequency histogram of lung voxels and is the
density value (g￿L
-1)a tw h i c h1 5 %o ft h ev o x e l sh a v e
lower densities [9,10] (Figure 2). This analysis combines
the raw data from both trials, thereby increasing the
numbers of patients and the robustness of the analysis.
CT scans were performed at baseline and annually
thereafter. In the EXACTLE study, there was an option
for additional scans at 30 months in those subjects who
had their participation prolonged from 24 months [15].
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ent scanner protocols. For the Danish-Dutch study,
scans were acquired during a breath hold (Dutch
patients) or during quiet tidal breathing (Danish
patients). The EXACTLE trial acquired scans during a
breath hold at maximum inspiration as summarised in
t h eo n l i n es u p p l e m e n tf o rD i r k s e net al [15]. In both
trials, CT scanners were carefully calibrated and all scan
data were centrally analysed by BioImaging Technolo-
gies, Inc. (Leiden, The Netherlands) using PulmoCMS®
Table 1 Comparison of study characteristics
Danish-Dutch trial EXACTLE trial
Genotype/phenotype PiZZ on IEF PiZZ or severe deficiency with AAT concentrations <11 μM
Lung function, FEV1 30-80% 25-80% and FEV1/VC ≤70% or
Kco NA ≤80% if spirometry normal
Exacerbations NA ≥1 exacerbation in the past 2 years
Smoking history Never or ex-smokers for >6 months
Cotinine checked every 4 weeks
Never or ex-smokers for >6 months Cotinine
checked at 1, 6, 24 and 30 months
Previous augmentation therapy NA Never or ≤1 month in past 2 years
Study design Randomised, double-blind, placebo-controlled Randomised, double-blind, placebo-controlled
AAT dosing 250 mg￿kg
-1 body weight AAT 60 mg￿kg
-1 body weight AAT
Treatment interval Every 4 weeks Every week
Placebo 625 mg￿kg
-1 body weight albumin 2% albumin
Centres 2 (Copenhagen, Leiden) 3 (Copenhagen, Birmingham, Malmö)
Duration of study Minimum 3 years 24 months (optional 6-months extension)
Study period January 1991 to August 1997 November 2003 to December 2006
Primary endpoints FEV1 measured by home spirometry twice daily Change in PD15 measured by CT
Other endpoints Change in PD15 measured by CT Exacerbations
Lung function (FEV1,K CO)
Quality of life (SGRQ)
AAT: alpha-1 antitrypsin; EXACTLE: Exacerbations and Computed Tomography scan as Lung Endpoints; IEF: isoelectric focusing; Kco: carbon monoxide transfer
coefficient; NA: not applicable; PD15: 15
th percentile lung density; SGRQ: St George’s Respiratory Questionnaire; VC: vital capacity. CT: computed tomography.
Table 2 Patient baseline demographic characteristics*
Danish-Dutch trial EXACTLE trial Combined data
AAT
(n = 27)
Placebo
(n = 27)
AAT
(n = 38)
Placebo
(n = 39)
AAT
(n = 60)
Placebo
(n = 59)
p value
Age (y) 48.0 ± 7.99 47.5 ± 7.29 54.7 ± 8.4 55.3 ± 9.8 51.6 ± 9.03 51.8 ± 9.73 0.808
Sex (n) male/female 18/9 16/11 25/13 16/23 38/22 29/30 0.093
Smoking status (n, ex/never) 27/0 27/0 34/4 35/4 56/4 56/3 0.748
Body mass index (kg￿m
2) 23.3 ± 3.15 24.4 ± 2.70 24.3 ± 3.3 24.3 ± 3.5 24.0 ± 3.3 24.5 ± 3.2 0.355
FEV1 (L), median 1.63 ± 0.49
1.63
1.72 ± 0.53
1.61
1.44 ± 0.60
1.14
1.35 ± 0.62
1.14
1.55 ± 0.56
1.47
1.48 ± 0.63
1.38 0.553
FEV1% predicted, median 47.3 ± 11.4
48.6
51.2 ± 14.5
49.0
46.3 ± 19.6
41.1
46.6 ± 21.0
39.5
48.0 ± 16.4
47.2
47.9 ± 18.6
43.1 0.949
Danish-Dutch trial EXACTLE trial Combined data
AAT (n = 27) Placebo (n = 27) AAT (n = 38) Placebo (n = 39) AAT (n = 60) Placebo (n = 59) p value
VC % predicted 114 ± 14.7 117 ± 16.4 94 ± 21.8 98 ± 23.2 103.1 ± 21.8 104.7 ± 23.9 0.789
DLCO% predicted Median 59.7 ± 16.0
57.0
60.1 ± 16.3
65.0
50.7 ± 19.5
47.6
52.2 ± 15.2
50.1
56.3 ± 17.3
56.1
55.7 ± 15.9
56.0 0.797
KCO % predicted 62.2 ± 17.62 59.9 ± 16.9 55.3 ± 21.0 56.5 ± 14.8 60.0 ± 18.9 58.6 ± 15.5 0.619
Unadjusted PD15 (g￿L
-1) 71.41 ± 20.87 75.56 ± 25.53 47.98 ± 19.07 45.48 ± 16.95 58.88 ± 23.03 59.79 ± 25.83 0.844
TLC-adjusted PD15
† (g￿L
-1) 59.9 ± 11.03 62.98 ± 13.49 54.6 ± 17.4 53.9 ± 16.0 57.1 ± 15.2 58.2 ± 15.7 0.691
Lung volume (L) 5.71 ± 1.27 5.52 ± 1.34 7.46 ± 1.60 7.27 ± 1.78 6.61 ± 1.67 6.35 ± 1.69 0.300
* Values are mean ± SD unless otherwise indicated.
†TLC-adjusted PD15: CT lung density multiplied by CT-measured total lung volume and divided by the individual patient’s predicted TLC.
For the CT densitometric analyses, the modified ITT population was used.
The combined analysis was based on the modified ITT population and did not include the data for 6 subjects who participated in EXACTLE, but who had also
participated in the earlier Danish-Dutch study.
AAT: alpha-1 antitrypsin; DLco: diffusion capacity of the lung for carbon monoxide; EXACTLE: Exacerbations and Computed Tomography scan as Lung Endpoints;
Kco: carbon monoxide transfer co-efficient; PD15: 15
th percentile lung density; TLC: total lung capacity; VC: vital capacity.
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EXACTLE study, and by Leiden University Medical
Centre for the Danish-Dutch study.
Data analysis and FEV1
We also took the opportunity to review the FEV1 decline
from both studies using all available data and a slope ana-
lysis for the patients included in the integrated analysis.
From the original Danish-Dutch study we were, however,
unable to retrieve spirometry from 4 of the subjects.
Volume correction of CT Scans
The level of inspiration during scan acquisition is re-
cognised to influence lung density and reduce the
reproducibility of CT. In the chosen method (statistical/
endpoint analysis method), volume correction was made
by including the change in log-transformed total lung
volume (TLV) as a covariate in the statistical model as
described [14]. This method corrects for intra-patient
differences in inspiration between scans as well as inter-
patient differences in technique between centres.
Statistical analysis
The raw data from the Danish-Dutch and EXACTLE
studies were retrieved and combined. A study ID vari-
able was included in the integrated analysis database to
identify the records in the Danish-Dutch or EXACTLE
studies.
All CT scan analyses were based on the modified
intent-to-treat (ITT) population, which included (in
common with the ITT) all randomised subjects who
received the study therapy. However, those subjects in
the modified ITT population also had to have one valid
CT scan measurement at baseline and at least one valid
CT scan assessment at the Month 12 visit or after.
For the Danish-Dutch and EXACTLE studies, PD15
was analysed using an analysis of covariance (ANCOVA)
model with change from baseline to the last CT scan
measurement in PD15 as the dependent variable, treat-
ment and centre as fixed factors, and change in loga-
rithm of CT-measured TLV and baseline measurement
as covariates (statistical/endpoint analysis method).
For the combined data of the integrated analysis, the
study ID was added to the model as a fixed effect. The
ANCOVA model included the change from baseline to
Figure 1 Patient disposition by treatment (patients providing CT data). AAT: alpha-1 antitrypsin; EXACTLE: Exacerbations and Computed
Tomography scan as Lung Endpoints.
Figure 2 Measurement of progression of emphysema.
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(EXACTLE versus Danish-Dutch), treatment, centre and
change in logarithm of lung volume as fixed factors, and
baseline measurement as covariate.
Results
Patient disposition and baseline characteristics
CT densitometric measurements from a total of 119
patients were analysed (AAT, n = 60; placebo, n = 59).
In the Danish-Dutch study, CT data were obtained from
54 patients, comprising 26 patients from Denmark and
28 patients from The Netherlands. In the EXACTLE
study, 65 patients provided data, 27 from Denmark, 23
from the United Kingdom and 15 from Sweden. The
patient disposition by treatment is shown in Figure 1.
In the Danish-Dutch study, the mean (range) length of
exposure was 2.52 (0.9-4.2) years to AAT, and 2.55 (0.9-
3.9) years to placebo. The corresponding values in the
EXACTLE study were 2.23 (1.1-2.6) and 2.18 (0.8-2.6)
years, respectively. For the combined data from both
studies, the mean (range) length of exposure to AAT
was 2.36 (0.9-4.2) years and to placebo, 2.33 (0.9-3.9)
years.
The characteristics for patients at baseline are sum-
marised in Table 2. Baseline demographics for patients
enrolled into the Danish-Dutch and EXACTLE studies
were comparable, although patients in the EXACTLE
study were slightly older and had a lower FEV1%p r e -
dicted. For the combined data, there were no statistically
significant differences between the group receiving AAT
or placebo with respect to age or body mass index.
There were some gender differences between the treat-
ment groups, with more male subjects in the active
treatment group, although this was not statistically sig-
nificant (p = 0.093).
All patients fulfilled the physiological inclusion criteria
shown in Table 1. There were no statistically significant
differences at baseline between the treatment groups
with regard to these parameters. There was also no sig-
nificant difference in total lung capacity-adjusted PD15
between the 2 groups at baseline (p = 0.691).
CT densitometric progression
From the Danish-Dutch study, the least squares mean
change in PD15 from baseline to endpoint was greater in
the placebo group than in the active group (3.155; p =
0.049; Table 3). Combined data from the Danish-Dutch
and EXACTLE studies confirmed the reduction in pro-
gression in patients receiving augmentation therapy
(-6.379 g￿L
-1 [placebo] versus -4.082 g￿L
-1 [AAT]; p =
0.006; Figure 3), which is approximately equivalent to
-2.74 and -1.73 g￿L
-1￿yr
-1, respectively. Therefore, using
the most sensitive statistical/endpoint analysis method of
volume correction, the separate and integrated analysis of
the 2 trials demonstrated a significant reduction in the
loss of lung tissue for subjects receiving treatment with
IV AAT in comparison with those receiving placebo.
FEV1 decline
The FEV1 declined significantly in both the combined
treated and placebo groups. The average annualised differ-
ence in FEV1 loss was 13 mL￿yr
-1 greater in the treated
group although this is within the error of measurement
(95% CI, -38 to 13; p = 0.321).
Discussion
Until now, a suitably powered double-blind randomised
trial of the clinical effectiveness of AAT augmentation
therapy has been lacking. The individual and combined
analysis of the Danish-Dutch and EXACTLE trials con-
firms that AAT augmentation therapy has a beneficial
effect on the decline in lung density, which is a measure
of the progression of emphysema.
AAT augmentation therapy is an accepted therapeutic
regimen [6], and an earlier observational study showed
better overall survival and reduced FEV1 decline (albeit
in a subset with moderate airflow obstruction) for
patients receiving therapy with varying regimens [16].
Whereas the recommended regimen is 60 mg￿kg
-1 body
weight per week, other adopted approaches are likely to
be as effective if the nadir AAT level is mostly above
the putative protective threshold of 11 μM.
Preservation of normal lung structure has been the
long-term aim of preventive therapy in chronic obstruc-
tive pulmonary disease (COPD). However, studies of
this concept have used FEV1 as the endpoint, since it is
not only a defining feature of COPD but also reflects
patients with a variety of phenotypes, including those
with small airways disease and emphysema. Moreover,
FEV1 is a reasonable marker of a patient’s health status
and exercise capacity [17], and has previously been con-
sidered to be the best predictor of respiratory and all-
cause mortality [18]. This has led to the tenet that the
maintenance of FEV1 reflects disease stability or a con-
sequent reduction in mortality. Nevertheless, FEV1 is a
poor surrogate measure for the presence and severity of
emphysema and its progression. For instance, it has
been demonstrated that patients with apical emphysema
may have a preserved FEV1 in both AAT deficiency
[8,19] and usual COPD [20].
The FEV1 data from this combined study confirm that
even doubling the number of subjects is inadequate to
verify whether augmentation therapy affects this non-
specific and relatively insensitive outcome of emphy-
sema. Much larger numbers of subjects studied over a
longer period of time are required [4] in order to deter-
mine the response of therapy on FEV1,e v e nt h o u g h
longitudinal CT data have confirmed that decline in
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only if sufficient data are analysed [10]. Extensive obser-
vational studies of lung density in AAT deficiency using
CT scanning have demonstrated that this parameter not
only relates to progressive reduction in FEV1 [10], health
status and exercise capacity [11], but is indeed a better
predictor of all-cause mortality than FEV1 [13]. It is pos-
sible to extrapolate the findings of this combined analy-
sis to conventional measures such as the FEV1 using
previously published data [10]. This indicates that the
reduction in densitometry quantified here (ྜ1 HU/year)
is equivalent to about a 38 ml difference in FEV1 decline
in patients in GOLD stage 2.
However as indicated above the decline in FEV1 is not
linear throughout the disease process. Therefore, for this
and other reasons, stabilisation of emphysema progres-
sion, as indicated by CT densitometry, would be as
important an aim, if not more so, than preserving FEV1.
The current combined analysis of the only 2 controlled
clinical trials completed to date has confirmed that AAT
augmentation therapy significantly reduces the decline
in lung density, and may thus reduce the future risk of
mortality as well as the deterioration in health status.
With AAT augmentation therapy becoming widely
accepted throughout the United States and Europe, the
ability to deliver appropriately powered placebo-controlled
clinical trials, particularly those requiring a physiological
measurement outcome, has become difficult to justify ethi-
cally and even more difficult to deliver. The current analy-
sis, however, provides evidence of augmentation therapy
reducing the rate of progression of lung tissue loss. The
data, therefore, permit future studies to be powered for
comparison of different therapeutic regimens using CT
scans rather than physiology (either FEV1 or gas transfer).
However, it should also be noted that even CT scans, as
well as accepted physiological measurements, are only sur-
rogate measures of emphysema. Importantly, the change
in physiological endpoints varies throughout the course of
the disease, with FEV1 decline being greatest in subjects
with moderate airflow obstruction (35-79% of predicted)
[16] and gas transfer decline being greatest in those with
most severe disease [7]. On the other hand, loss of lung
d e n s i t ya sa s s e s s e db yP D 1 5s h o w sam o r ec o n s t a n t
change across all stages of disease severity [10], suggesting
that it is a better marker of the continuing disease process.
It is not always feasible to conduct powered clinical
studies [21], and sometimes a combination of compar-
able studies is necessary. For example, meta-analysis of
several studies has been used to support the use of anti-
biotics in acute exacerbations of COPD [22].
In clinical medicine, meta-analyses are accepted and
useful tools that combine results from several studies
to draw conclusions about clinical effectiveness. These
can be either based on the analysis of published data
(so-called ‘aggregated analysis’) or by pooling individual
patient data (also termed ‘integrated analysis’) [23]. Trials
with different protocols, but with common characteris-
tics, can be pooled for these analyses. An integrated ana-
lysis based on individual patient data offers numerous
advantages over the use of aggregated data; it is more
Table 3 Changes in unadjusted 15
th percentile lung density (g￿L
-1) using endpoint analysis
Danish-Dutch trial EXACTLE trial Combined data
Statistic AAT
(n = 27)
Placebo
(n = 27)
AAT
(n = 36)
Placebo
(n = 35)
AAT
(n = 60)
Placebo
(n = 59)
Change from baseline to last CT scan, LS mean -6.409 -9.564 -2.645 -4.117 -4.082 -6.379
Estimated treatment difference between changes from baseline, 95% CI
† 3.155
(0.008-6.301)
1.472
(0.009-2.935)
2.297
(0.669-3.926)
p value for treatment difference 0.049 0.049 0.006
For the CT densitometric analyses, the modified ITT population was used. The combined analysis was based on the modified ITT population and did not include
the data for 6 subjects who participated in EXACTLE, but who had their data included in the earlier Danish-Dutch study.
†AAT treatment minus placebo.
AAT: alpha-1 antitrypsin; CT: computed tomography; EXACTLE: Exacerbations and Computed Tomography scan as Lung Endpoints; LS: least squares.
Figure 3 Progression of emphysema in AAT-treated versus
placebo-treated subjects (modified ITT). *Estimated treatment
difference between mean changes in unadjusted 15
th percentile
lung density from baseline. AAT: alpha-1 antitrypsin; LS: least
squares; PD15: 15
th percentile lung density.
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to different conclusions [23,24]. This approach has been
used more frequently in recent years [24] and also allows,
as aggregate analyses similarly do, for the inclusion of dif-
ferent drug substances belonging to the same drug class,
and different predefined clinical endpoints in the source
studies [25,26], provided that the studies have common
characteristics to enable the pooling of data.
Although there were some differences in study charac-
teristics, the EXACTLE and Danish-Dutch trials both
had a randomised, placebo-controlled, blinded, parallel
design and had a similar CT scan protocol. The 2 stu-
dies were comparable with regard to treatment drug,
treatment duration and patient characteristics. There is
a general belief that maintaining AAT above a protective
level of 11 μM is the key to a successful therapeutic out-
come, and both studies had treatment regimens that are
able to maintain protective levels of AAT, either consis-
tently, or for at least 3 out of the 4 weeks in the
monthly regimen used in the Danish-Dutch trial [14].
The Jadad scale is widely used to assess the methodo-
logical quality of clinical trials [27,28]. When evaluated
on this scale, the design of the 2 studies met the stan-
dards required for their results to be included in a
meta- or integrated analysis. Although the principle of
meta- or integrated analyses is based on the inclusion of
several studies, p values are reported without statistical
adjustment of the alpha level.
Integrating the data from the 2 studies increased the
numbers and hence the power of the observations. By
using the most sensitive method for assessing emphy-
sema progression (as measured by tissue loss) with end-
point analysis of PD15, the mean data demonstrate a
deceleration of lung tissue loss with AAT augmentation
therapy with a high degree of statistical significance. It
is, however, recognised that progression even in CT
densitometry varies between individuals. Thus adequate
historical data will remain a prerequisite to therapeutic
decision making. Furthermore, it should be noted that
the treatment effect may not be demonstrable for the
first 12 months of therapy [14,15]. The exact reasons
remain unknown but it is possible that a period of time
is required to reverse the established, destructive inflam-
matory process. This observation clearly has potential
impact on the design of future phase 2 and 3 studies in
AAT deficiency and support an end point analysis as
the best primary outcome.
In conclusion, the overall results are supportive of the
efficacy of AAT augmentation therapy and, importantly,
provide confirmatory data to power and analyse future
alternative strategies for which long-term IV placebo
arms cannot be justified ethically.
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